{"id":448452,"date":"2019-11-16T18:00:02","date_gmt":"2019-11-16T18:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=448452"},"modified":"2019-11-16T18:00:02","modified_gmt":"2019-11-16T18:00:02","slug":"mycoplasma-testing-market-opportunities-and-challenges","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/mycoplasma-testing-market-opportunities-and-challenges_448452.html","title":{"rendered":"Mycoplasma Testing Market: Opportunities and Challenges"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1573734111.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Mycoplasma Testing Market: Opportunities and Challenges\" src=\"https:\/\/www.abnewswire.com\/uploads\/1573734111.jpeg\" alt=\"Mycoplasma Testing Market: Opportunities and Challenges\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>The key players in the mycoplasma testing market include Thermo Fisher Scientific Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), SGS S.A. (Switzerland), American Type Culture Collection (U.S.), Bionique Testing Laboratories, Inc. (U.S.)<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">With the growth in outsourcing R&#038;D activities, the demand for mycoplasma testing services from CROs is estimated to increase. The rise in outsourcing thus provides significant growth opportunities for the market.<\/div>\n<p style=\"text-align: justify;\">The <a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/mycoplasma-testing-market-136509856.html\">Mycoplasma Testing Market<\/a> is expected to reach USD 943.4 Million by 2022 from USD 523.3 Million in 2017, at a CAGR of 12.5% during the forecast period, as per a report by MarketsandMarkets.&nbsp;<\/p>\n<p> <strong>Download PDF Brochure:<br \/> <\/strong><a href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=136509856&amp;utm_source=AbNews-16-Nov\">https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=136509856<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Why increasing pharmaceutical outsourcing<\/strong><strong> offers an opportunity?<\/strong><\/p>\n<p style=\"text-align: justify;\">The R&amp;D expenditure in the pharmaceutical industry is very high. According to PhRMA, its member companies invested an estimated USD 58.8 billion in research and development (R&amp;D) in 2015, an increase of 10.3% from 2014. Contract research organizations act as outsourcing partners for pharmaceutical and biotechnology companies and academic institutes. Many pharmaceutical and biotechnology companies and academic institutes opt to outsource functions like manufacturing, clinical trial management, and drug discovery to CROs. Pharmaceutical research outsourcing enables these organizations to decrease their operational costs. Furthermore, owing to technological advancements and the emergence of new technologies, it is not feasible for companies to undertake all testing functions in-house. CROs can afford to invest in an extensive drug discovery infrastructure as they cater to multiple clients. This makes investing in advanced techniques like PCR, ELISA, and cell line authentication and characterization tests a cost-effective option for CROs. With the help of CROs, pharmaceutical and biotechnology companies can reduce their operational costs and R&amp;D budgets. With the growth in outsourcing R&amp;D activities, the demand for mycoplasma testing services from CROs is estimated to increase. The rise in outsourcing thus provides significant growth opportunities for the market.<\/p>\n<p style=\"text-align: justify;\"><strong>Why shortage of skilled professionals<\/strong><strong> is a key challenge?<\/strong><\/p>\n<p style=\"text-align: justify;\">The success of mycoplasma tests depends mainly on the expertise of the analysts themselves as much as the environmental conditions under which the test is performed. For optimal efficacy, mycoplasma testing needs to be conducted by skilled professionals with sufficient knowledge of the nuances of this field. Handling the instruments used in mycoplasma testing also requires expertise. Consequently, the dearth of a sufficiently skilled workforce poses a key challenge to the growth of the mycoplasma testing market.<\/p>\n<p> <strong>Request Sample Pages:<br \/> <\/strong><a href=\"https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=136509856&amp;utm_source=AbNews-16-Nov\">https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=136509856<\/a><\/p>\n<p> <strong>Browse Related Reports:<\/p>\n<p> <\/strong><a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/sterility-testing-market-208866931.html\">Sterility Testing Market<\/a> by Product (Instruments, Services, Kits and Reagents), Test (Membrane Filtration Sterility Testing, Direct Inoculation Sterility Testing), Application (Pharmaceutical &amp; Biotechnology, Medical Devices) &#8211; Global Forecasts to 2021<\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/pyrogen-testing-market-255266155.html\">Pyrogen Testing Market<\/a> by Product (Instruments, Services, Kits and Reagents), Application (Pharmaceutical &amp; Biotechnology, Medical Devices, Other), Test (In Vitro, Lal, Gel Clot, Turbidimetric, Chromogenic, Rabbit) &#8211; Global Forecasts to 2021<strong><\/p>\n<p> <\/strong><strong>About MarketsandMarkets&trade;<\/strong> <\/p>\n<p> MarketsandMarkets&trade; provides quantified B2B research on 30,000 high growth niche opportunities\/threats which will impact 70% to 80% of worldwide companies&rsquo; revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets&trade; for their painpoints around revenues decisions.<\/p>\n<p> Our 850 fulltime analyst and SMEs at MarketsandMarkets&trade; are tracking global high growth markets following the &#8220;Growth Engagement Model &ndash; GEM&#8221;. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write &#8220;Attack, avoid and defend&#8221; strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets&trade; now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets&trade; is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations\/disruptions early to the market by providing them research ahead of the curve.<\/p>\n<p> MarketsandMarkets&rsquo;s flagship competitive intelligence and market research platform, &#8220;Knowledge Store&#8221; connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/marketsandmarkets.com_17712.html\" rel=\"nofollow\">MarketsandMarkets<\/a><br \/><strong>Contact Person:<\/strong> Mr. Shelly Singh<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=mycoplasma-testing-market-opportunities-and-challenges\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 1-888-600-6441<br \/><strong>Address:<\/strong>630 Dundee Road   Suite 430 <br \/><strong>City:<\/strong> Northbrook<br \/><strong>State:<\/strong> IL<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/mycoplasma-testing-market-136509856.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.marketsandmarkets.com\/Market-Reports\/mycoplasma-testing-market-136509856.html<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/mycoplasma-testing-market-136509856.html\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=mycoplasma-testing-market-opportunities-and-challenges\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The key players in the mycoplasma testing market include Thermo Fisher Scientific Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), SGS S.A. (Switzerland), American Type Culture Collection (U.S.), Bionique Testing &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/mycoplasma-testing-market-opportunities-and-challenges_448452.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,412,406],"tags":[],"class_list":["post-448452","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-News-Current-Affairs","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/448452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=448452"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/448452\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=448452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=448452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=448452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}